Analytical Data
-
Gene name
STK32A
- Application
-
Alternative Names
Yet another novel kinase 1
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8WU08
-
Expression Region
1-166aa
-
Molecular Weight
46.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
STK32A, a member of the serine/threonine kinase family, has garnered significant attention in the field of molecular biology due to its potential role in various cellular processes, including cell proliferation, apoptosis, and signal transduction. It is particularly intriguing because of its involvement in immune responses and tumorigenesis. Researchers have focused on the recombinant production of STK32A to facilitate functional studies, antibody generation, and high-throughput screenings that can elucidate its biological significance. The expression and purification of STK32A as a recombinant protein enable further analyses regarding its enzymatic activity, interaction with substrates, and regulatory mechanisms. Understanding STK32A's structure-function relationship is crucial not only for unraveling its biological roles but also for exploring its potential as a therapeutic target. Consequently, studies on STK32A have expanded our knowledge of its contributions to disease mechanisms, particularly in cancers and inflammatory conditions, making it a promising candidate for future therapeutic interventions and biomarker development. Through the application of advanced techniques in recombinant protein production, researchers aim to overcome previous challenges in studying this kinase, thus paving the way for innovative approaches in drug discovery and personalized medicine.
